Did you know –

Approximately 1 in 10 of postmenopausal women aged <65years  will have a fracture during a 10-year period.fractures in adults 50 to 65 years of age account for approximately one fourth of all fractures in adults over 50 years of age

Current treatment guidelines are-an intravenous zoledronate  infusion annually or every 18 months.

Zoledronate reduces the incidence of fracture among osteopenic and osteoporotic populations and it has an excellent safety profile for up to 9 years with annual treatment But frequent injections are needed to prevent fracture risk. Studies showed- as zoledronate has prolonged duration of action — the effects of a single 5-mg dose on bone mineral density and bone turnover are stable and persist well beyond 5 years. Fracture risk remains reduced for several years after treatment discontinuation, and in one post hoc analysis, reductions in the incidence of total and vertebral fractures after 3 years were similar among patients who received a single 5-mg dose of zoledronate and among those who received an annual dose.

Latest prospective study over a period of 10 years showed-  zoledronate administered at baseline and 5 years was effective in preventing morphometric vertebral fracture in early postmenopausal women.

fracture-prevention strategies for early postmenopausal women can be effective,as seen with 9-year trial of estrogen therapy in women with a mean age of 48 years at baseline who had surgically induced menopause which showed the prevention of vertebral fractures.

Although the benefit for individual persons at low risk for fracture is small, infrequent infusions of zoledronate could substantially reduce the number of fractures that occur in the population. Thus, the very infrequent infusions of zoledronate to prevent vertebral fractures and bone loss in early postmenopausal women offers a clinically realistic therapeutic option for women who are concerned about bone loss or their future risk of fracture.